Lundbeck CDM delivers end-to-end API and drug product solutions from development to commercial scale.
01 2Brintellix
02 9Brintellix/Trintellix
03 4Trintellix
04 4Trintellix/Brintellix
Lundbeck CDM delivers end-to-end API and drug product solutions from development to commercial scale.
Main Therapeutic Indication : CNS & Anesthesia
Currency : USD
2020 Revenue in Millions : 505
2019 Revenue in Millions : 460
Growth (%) : 10
Lundbeck CDM delivers end-to-end API and drug product solutions from development to commercial scale.
Main Therapeutic Indication : Neurology
Currency : USD
2021 Revenue in Millions : 537
2020 Revenue in Millions : 496
Growth (%) : 14
Lundbeck CDM delivers end-to-end API and drug product solutions from development to commercial scale.
Main Therapeutic Indication : Neurology
Currency : USD
2022 Revenue in Millions : 616
2021 Revenue in Millions : 537
Growth (%) : 15
Lundbeck CDM delivers end-to-end API and drug product solutions from development to commercial scale.
Main Therapeutic Indication : Neurology
Currency : USD
2023 Revenue in Millions : 623
2022 Revenue in Millions : 616
Growth (%) : 1
Lundbeck CDM delivers end-to-end API and drug product solutions from development to commercial scale.
Main Therapeutic Indication : Neurology
Currency : USD
2024 Revenue in Millions : 672
2023 Revenue in Millions : 623
Growth (%) : 8
Lundbeck CDM delivers end-to-end API and drug product solutions from development to commercial scale.
Main Therapeutic Indication : Neuroscience and Mental Health
Currency : USD
2015 Revenue in Millions : 28
2014 Revenue in Millions : 94
Growth (%) : 236%
Lundbeck CDM delivers end-to-end API and drug product solutions from development to commercial scale.
Main Therapeutic Indication : Neuroscience/Mental Health
Currency : USD
2014 Revenue in Millions :
2013 Revenue in Millions :
Growth (%) :
Lundbeck CDM delivers end-to-end API and drug product solutions from development to commercial scale.
Main Therapeutic Indication : Neurological/Mental Disorders
Currency : USD
2017 Revenue in Millions : 283
2016 Revenue in Millions : 188
Growth (%) : 50
Lundbeck CDM delivers end-to-end API and drug product solutions from development to commercial scale.
Main Therapeutic Indication : Neurological/Mental Disorders
Currency : USD
2018 Revenue in Millions : 327
2017 Revenue in Millions : 249
Growth (%) : 31%
Lundbeck CDM delivers end-to-end API and drug product solutions from development to commercial scale.
Main Therapeutic Indication : CNS & Anesthesia
Currency : USD
2019 Revenue in Millions : 424
2018 Revenue in Millions : 327
Growth (%) : 30
